Cold sore virus modified to fight kidney cancer in new trial
NCT ID NCT07218692
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests a new treatment for advanced kidney cancer that has spread and worsened after immunotherapy. The treatment combines a modified cold sore virus (RP2) that attacks tumor cells and activates the immune system, with a targeted drug (tivozanib) that blocks tumor growth and blood vessel formation. The trial aims to see if this combination is safe and effective for 35 adults whose cancer has not responded to standard immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.